Hot flushes, bone mineral density, and fractures in older postmenopausal women

Obstetrics and Gynecology

Volumn 109, Issue 4, 2007, Pages 841-847

  Huang, Alison ^a   Grady, Deborah ^b   Blackwell, Terri ^b   Bauer, Douglas ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HOT FLUSH; HUMAN; INTERVIEW; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK; SELF REPORT;

AGED; BONE DENSITY; COHORT STUDIES; FEMALE; FRACTURES, BONE; HOT FLASHES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RISK; SEVERITY OF ILLNESS INDEX;

EID: 34147163385     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000258297.02413.6e     Document Type: Article

References (25)

1. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-61.
2. Vasomotor symptoms. Obstet Gynecol 2004;104 suppl: 106S-17S.
3. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-25.
4. Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause 2005;12:156-9.
5. Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000;95:804-9.
6. Leal Hernandez M, Abellan Aleman J, Carbonell Meseguer LF, Diaz Fernandez, J, Garcia Sanchez, FA, Martinez Selva, JM.. Influence of the presence of hot flashes during menopause on the metabolism of nitric oxide: effects of hormonal replacement treatment [in Spanish]. Med Clin (Barc) 2000;114:41-5.
7. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26:1358-61.
8. Menon RK, Okonofua FE, Agnew JE, Thomas M, Bell JO'Brien PM, et al. Endocrine and metabolic effects of simple hysterectomy. Int J Gynaecol Obstet 1987;25:459-63.
9. Naessen T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporos Int 1992;2:225-31.
10. Lee SJ, Kanis JA. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner 1994;24:127-34.
11. Salamone LM, Gregg E, Wolf RL, Epstein RS, Black D, Palermo L, et al. Are menopausal symptoms associated with bone mineral density and changes in bone mineral density in premenopausal women? Maturitas 1998;29:179-87.
12. Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes V, et al. Effects of ultralow-dose transdermal estradiol on post-menopausal symptoms in women aged 60 to 80 years. Menopause 2006;13:130-8.
13. Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-18.
14. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063-73.
15. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
16. Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, et al. Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 1996;11:626-37.
17. Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK. Comparative calibration without a gold standard. Stat Med 1997;16:1889-905.
18. Sheikh JI. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, editor. Clinical gerontology: a guide to assessment and intervention. New York (NY): The Haworth Press; 1986. p. 165-73.
19. Modelska K, Litwack S, Ewing SK, Yaffe K. Endogenous estrogen levels affect sexual function in elderly post-menopausal women. Maturitas 2004;49:124-33.
20. Vittinghoff E, Glidden D, Shiboski S, McCulloch C. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. New York (NY): Springer; 2005.
21. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-51.
22. Jolly EE, Bjarnason NH, Neven P, Plouffe L Johnston CC, Jr, Watts SD, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44.
23. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York (NY): Wiley; 1980.
24. von Muhlen DG, Soroko S, Kritz-Silverstein Barrett-Connor E. Vasomotor symptoms are not associated with reduced bone mass in postmenopausal women: the Rancho Bernardo Study. J Womens Health Gend Based Med 2000;9:505-11.
25. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-90.